secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001654954-22-016569
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata receives Nasdaq extension to June 12, 2023 to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted extra 180 days (to June 12, 2023) to meet minimum $1.00 bid price per share.
- Company previously received June 17, 2022 notice; initial 180-day grace period expired Dec 14, 2022.
- May consider a reverse stock split to regain compliance if needed.
- If compliance not regained by June 12, 2023, Nasdaq will start delisting proceedings.
- Delisting risk could adversely affect liquidity, financing ability, and stock price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422016569/0001654954-22-016569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422016569/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-016569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer